---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095414"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:07:53.660375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M

## Summary
- Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
- Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.
- R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.
- Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.
- Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024.

## SEC filing metadata
- accession: 0000950170-24-095414
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/0000950170-24-095414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/srzn-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095414
- JSON: https://secwatch.observer/filing/0000950170-24-095414.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.